Skip to content

Study · Not a test of the peptide alone · 2026

2 results

GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study.

Thomas O, Coulson JM

British journal of clinical pharmacology8 Nov 2025Cited by 1 (Europe PMC)

PMID41204831 (opens in a new tab)PMCIDPMC12746371 (opens in a new tab)DOI10.1002/bcp.70335 (opens in a new tab)PepBankPUB-41204831
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

The impact of GLP-1 or GIP/GLP-1 receptor agonist use on unscheduled care is not well-described. We conducted a prospective, observational study using opportunistic screening by clinicians as a first step to understanding the effect of GLP-1 or GIP/GLP-1 agonists on Emergency Department presentations and to guide future studies. Data were collected from April to August 2025 at a single centre for any nontrauma adult patient who self-reported GLP-1 or GIP/GLP-1 agonist exposure. Fifty-six cases were identified, 51 reported tirzepatide use, three subcutaneous semaglutide, one oral semaglutide and one dulaglutide. In 79% of cases (CI95% 66% to 88%), the presenting features were due to GLP-1 or agonist use. Presentations were greatest in the lowest and highest deprivation quintiles and a significant number had coexisting depression. There is a need for formal observational studies to assess the impact of GLP-1 or GIP/GLP-1 agonists on unscheduled care and explore these tentative associations.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In adults who attended an emergency department and reported GLP-1 or GIP/GLP-1 agonist use, 79% of presentations were due to the agonist (pooled across agonists, mostly tirzepatide).

    In plain wordsIn adults attending an emergency department, 79% of visits by people using GLP-1 or GIP/GLP-1 drugs were linked to the drug.

    Peptide
    Tirzepatide
    Outcome
    Not applicableEmergency presentations due to GLP-1 or GIP/GLP-1 agonist use
    Study

    n = 56

    Outcome group
    Adverse events · Whole body

    Measurements

    Presentations due to agonist use
    79%
    emergency department cases
    95% CI
    66 to 88%
    emergency department cases

    Source sentences

    Summary
    In 79% of cases (CI95% 66% to 88%), the presenting features were due to GLP-1 or agonist use.
    2 context sentences
    Summary · context
    Data were collected from April to August 2025 at a single centre for any nontrauma adult patient who self-reported GLP-1 or GIP/GLP-1 agonist exposure.
    Summary · context
    Fifty-six cases were identified, 51 reported tirzepatide use, three subcutaneous semaglutide, one oral semaglutide and one dulaglutide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  2. 02HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In adults who attended an emergency department and reported GLP-1 or GIP/GLP-1 agonist use, 79% of presentations were due to the agonist (pooled across agonists, mostly tirzepatide).

    In plain wordsIn adults attending an emergency department, 79% of visits by people using GLP-1 or GIP/GLP-1 drugs were linked to the drug.

    Peptide
    Semaglutide
    Outcome
    Not applicableEmergency presentations due to GLP-1 or GIP/GLP-1 agonist use
    Study

    n = 56

    Outcome group
    Adverse events · Whole body

    Measurements

    Presentations due to agonist use
    79%
    emergency department cases
    95% CI
    66 to 88%
    emergency department cases

    Source sentences

    Summary
    In 79% of cases (CI95% 66% to 88%), the presenting features were due to GLP-1 or agonist use.
    2 context sentences
    Summary · context
    Data were collected from April to August 2025 at a single centre for any nontrauma adult patient who self-reported GLP-1 or GIP/GLP-1 agonist exposure.
    Summary · context
    Fifty-six cases were identified, 51 reported tirzepatide use, three subcutaneous semaglutide, one oral semaglutide and one dulaglutide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.